• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model.

作者信息

Müller Peter, Baldauf Conny K, Haage Tobias R, Charakopoulos Emmanouil, Böttcher Martin, Bhuria Vikas, Mougiakakos Dimitrios, Schraven Burkhart, Fischer Thomas

机构信息

Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany.

Health Campus Immunology, Infectiology and Inflammation (GCI3), Medical Center, Otto-von-Guericke University, Magdeburg, Germany.

出版信息

Hemasphere. 2022 Apr 15;6(5):e717. doi: 10.1097/HS9.0000000000000717. eCollection 2022 May.

DOI:10.1097/HS9.0000000000000717
PMID:35449791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9015207/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ee/9015207/04a0035d27bd/hs9-6-e717-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ee/9015207/0ace71f92700/hs9-6-e717-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ee/9015207/04a0035d27bd/hs9-6-e717-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ee/9015207/0ace71f92700/hs9-6-e717-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ee/9015207/04a0035d27bd/hs9-6-e717-g002.jpg

相似文献

1
Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model.JAK2-V617F真性红细胞增多症小鼠模型中TNFR1和TNFR2的基因敲除
Hemasphere. 2022 Apr 15;6(5):e717. doi: 10.1097/HS9.0000000000000717. eCollection 2022 May.
2
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
3
Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.真性红细胞增多症、原发性骨髓纤维化和原发性血小板增多症中的细胞遗传学、JAK2和MPL突变
Rev Bras Hematol Hemoter. 2011;33(6):417-24. doi: 10.5581/1516-8484.20110116.
4
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.在参与RESPONSE研究的真性红细胞增多症患者中，鲁索替尼可降低JAK2 p.V617F等位基因负荷。
Ann Hematol. 2017 Jul;96(7):1113-1120. doi: 10.1007/s00277-017-2994-x. Epub 2017 Apr 30.
5
Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.采用克隆技术检测JAK2 V617F阴性真性红细胞增多症患者的JAK2外显子12突变
Acta Haematol. 2016;136(2):123-8. doi: 10.1159/000446798. Epub 2016 Jul 14.
6
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.JAK2 V617F 诱导小鼠发生红细胞增多症的分子发病机制与治疗
PLoS One. 2006 Dec 20;1(1):e18. doi: 10.1371/journal.pone.0000018.
7
Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.JAK2 V617F阴性真性红细胞增多症、红细胞增多症和原发性骨髓纤维化中的表型变异与新突变。
Exp Hematol. 2007 Nov;35(11):1641-6. doi: 10.1016/j.exphem.2007.08.010. Epub 2007 Oct 17.
8
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化中JAK2 V617F等位基因负荷——对疾病表型的影响
Eur J Haematol. 2007 Dec;79(6):508-15. doi: 10.1111/j.1600-0609.2007.00960.x. Epub 2007 Oct 23.
9
Polycythemia vera: the current status of preclinical models and therapeutic targets.真性红细胞增多症：临床前模型和治疗靶点的现状。
Expert Opin Ther Targets. 2020 Jul;24(7):615-628. doi: 10.1080/14728222.2020.1762176. Epub 2020 May 18.
10
Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.PRV-1 mRNA表达水平和JAK2V617F突变在真性红细胞增多症与继发性红细胞增多症鉴别诊断及干扰素或羟基脲治疗评估中的应用
Hematology. 2007 Dec;12(6):473-9. doi: 10.1080/10245330701384005.

引用本文的文献

1
Activation of integrin signaling up-regulates pro-inflammatory cytokines in JAK2-V617F positive hematopoietic cells.整合素信号的激活上调JAK2-V617F阳性造血细胞中的促炎细胞因子。
Cell Commun Signal. 2025 Aug 11;23(1):368. doi: 10.1186/s12964-025-02358-x.

本文引用的文献

1
Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F-induced disease.MPN 中的抗炎治疗：针对 JAK2-V617F 诱导疾病中的 TNFR1 和 TNFR2。
Blood Adv. 2021 Dec 14;5(23):5349-5359. doi: 10.1182/bloodadvances.2021004438.
2
Accelerated Phase of Myeloproliferative Neoplasms.骨髓增殖性肿瘤的加速期。
Acta Haematol. 2021;144(5):484-499. doi: 10.1159/000512929. Epub 2021 Apr 21.
3
Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.
Toll 样受体信号转导的缺陷负调控导致骨髓增殖性肿瘤中 TNF-α 过多。
Blood Adv. 2019 Jan 22;3(2):122-131. doi: 10.1182/bloodadvances.2018026450.
4
Dysregulated iron metabolism in polycythemia vera: etiology and consequences.真性红细胞增多症中铁代谢失调：病因与后果。
Leukemia. 2018 Oct;32(10):2105-2116. doi: 10.1038/s41375-018-0207-9. Epub 2018 Jul 24.
5
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion.自分泌 TNF 信号通过 TNFR2 依赖性方式有利于骨髓纤维化中的恶性细胞。
Leukemia. 2018 Nov;32(11):2399-2411. doi: 10.1038/s41375-018-0131-z. Epub 2018 Apr 18.
6
Genetic compensation: A phenomenon in search of mechanisms.基因补偿：一种尚待探寻作用机制的现象。
PLoS Genet. 2017 Jul 13;13(7):e1006780. doi: 10.1371/journal.pgen.1006780. eCollection 2017 Jul.
7
The thrombopoietin/MPL axis is activated in the Gata1 mouse model of myelofibrosis and is associated with a defective RPS14 signature.血小板生成素/MPL轴在骨髓纤维化的Gata1小鼠模型中被激活，并与RPS14特征缺陷相关。
Blood Cancer J. 2017 Jun 16;7(6):e572. doi: 10.1038/bcj.2017.51.
8
Myeloproliferative Neoplasms.骨髓增殖性肿瘤
N Engl J Med. 2017 Jun 1;376(22):2168-2181. doi: 10.1056/NEJMra1406186.
9
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.骨髓增殖性肿瘤与炎症：靶向恶性克隆还是炎症过程，或者两者兼而有之。
Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8.
10
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.骨髓增殖性肿瘤：十年的发现和治疗进展。
Am J Hematol. 2016 Jan;91(1):50-8. doi: 10.1002/ajh.24221.